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SObjective: The study objective was to evaluate the clinical outcomes of surgical decortication as the first line of
treatment for pleural empyema.
Methods:We analyzed the medical records of 111 patients who presented with empyema and were treated with
simple drainage or surgical decortication as the first line of treatment at Gangnam Severance Hospital, a tertiary
referral medical center in Seoul, Korea.
Results: Of 111 patients with empyema, 27 underwent surgical decortication as the first intervention. Surgical
decortication showed a better treatment success rate in all study subjects (96.3%, 26/27 patients) compared with
simple drainage (58.3%, 49/84 patients; P<.0001 for method comparison). After propensity-scored matching,
decortication resulted in a better outcome (95.0%, 19/20 patients) versus drainage (56.7%, 17/30 patients;
P ¼ .003). Surgical decortication as the first line of treatment for empyema was the best predictor of treatment
success after adjustment for compounding factors (odds ratio, 14.529; 95% confidence interval, 1.715-123.074;
P ¼ .014).
Conclusions: The first treatment choice for pleural empyema is a critical determinant of ultimate therapeutic
success. After adjusting for confounding variables, surgical decortication is the optimal first treatment choice
for advanced empyema. (J Thorac Cardiovasc Surg 2013;145:933-9)Supplemental material is available online.Pleural empyema is defined as the presence of purulent fluid
within the pleural space. Most empyemas occur in associa-
tion with pneumonia, although empyema has no relation
with pneumonia in approximately one third of patients.1
Empyema due to tuberculosis (TB) is increasingly prevalent
in TB-endemic countries.2,3 Empyema often causes
substantial morbidity and mortality.4 In 1962, the American
Thoracic Society5 described the 3 phases of empyema as
exudative (stage I), fibrinopurulent (stage II), and organiz-
ing (stage III). In the initial exudative stage, closed chest
drainage and appropriate antibiotic administration can com-
prise effective treatment. Antimicrobial therapy success-
fully resolves small uniloculated empyema with an 80%
success rate.6 However, in the later fibrinopurulent and or-
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The Journal of Thoracic and Capleural peel and fluid loculation. If initial noninvasive treat-
ment fails, surgical intervention involving thoracotomy and
decortication is an alternative choice. Depending on the
surgeon’s experience, surgical intervention can be per-
formed using minimally invasive techniques, such as decor-
tication by video-assisted thoracoscopic surgery (VATS), or
open thoracotomy. Although the optimal therapeutic ap-
proach for empyema remains undetermined, surgery has
been shown to be an effective treatment option, especially
in multiloculated empyema. On the other hand, the risks
of surgery need to be balanced against the expected benefits.
The evolutionary stages of pleural empyema are not clearly
defined, but rather represent a continuous spectrum of
events. Some patients with empyema have enough time to
undergo surgical therapy as an alternative choice, despite
the failure of attempted medical therapy. Other patients
have no time to undergo alternative therapies, because the
disease progresses rapidly with concomitant health deterio-
ration, and surgery is the only option. Thus, the first thera-
peutic choice for empyema should be made deliberately.
Empyema management traditionally has been empirical,
but recent data favor establishing more specific manage-
ment guidelines. In this study, we reviewed our clinical
experience in treating pleural empyema in both nontubercu-
lous and tuberculous scenarios.PATIENTS AND METHODS
Patient Characteristics
We retrospectively analyzed the medical records of 111 patients who
presented with empyema between January 2008 and July 2011 at Gangnam
Severance Hospital, a tertiary referral medical center in Seoul, Korea. Therdiovascular Surgery c Volume 145, Number 4 933
Abbreviations and Acronyms
ACCP ¼ American College of Chest
Physicians
APACHE II ¼ Acute Physiology and Chronic
Health Evaluation II
BMI ¼ body mass index
CCI ¼ Charlson Comorbidity Index
ECOG ¼ Eastern Cooperative Oncology
Group
TB ¼ tuberculosis
VATS ¼ video-assisted thoracoscopic surgery
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nosis of empyema. Data regarding clinical profile, initial and final diagno-
ses, and disease severity were recorded (Table 1). This study was approved
by the Institutional Review Board, Gangnam Severance Hospital, Yonsei
University College of Medicine (Institutional Review Board No: 3-2011-
0283), and the necessity for written informed consent was waived because
this was a retrospective study and patients were anonymized.
Empyema Cause
Pleural fluid was investigated by microbiological and biochemical
methods. Bacterial culture, Gram staining, acid-fast bacilli smears, and
Mycobacterium tuberculosis culture were performed on both pleural and
sputum samples. Biochemical analysis of pleural fluid included pH, glu-
cose level.
In our study, tuberculous empyemas were analyzed together with non-
tuberculous bacterial empyemas. Tuberculous pleural effusions are com-
mon findings in TB-endemic countries, and tuberculous empyema is
associated with high morbidity and mortality unless surgically treated. Pa-
tients presenting with pleural empyema should be assessed for tuberculous
empyema in TB-endemic countries.TABLE 1. Baseline characteristics of all study subjects
Variable Total (N ¼ 111)
Age, y 56.1  20.0
Gender, male, n (%) 88 (79.3)
BMI, kg/m2 21.6  3.7
Diabetes, n (%) 23 (20.7)
CCI, median (range) 0 (0-6)
Mean arterial pressure, mm Hg (mean  SD) 85.9  18.2
ECOG, n (%)
0 53 (47.7)
1 22 (19.8)
2 15 (13.5)
3 11 (9.9)
4 10 (9.0)
APACHE II score at diagnosis, median (range) 7 (0-33)
Diagnosis, n (%)
Parapneumonic 73 (65.8)
TB 33 (29.7)
Postoperative 4 (3.6)
Others 1 (0.9)
Duration of symptoms to admission, d 9.6  12.0
Duration of symptoms to treatment, d 13.5  10.1
Age, BMI, mean arterial pressure, and days are all presented as mean values  SD. BMI, B
Eastern Cooperative Oncology Group; APACHE II, Acute Physiology and Chronic Health
934 The Journal of Thoracic and Cardiovascular SurgPatient Inclusion Criteria, Disease Definition, and
Patient Grouping
Inclusion criteria were pleural empyema diagnosis and agemore than 18
years. Empyema was defined as septations or loculations identified in the
pleural space by computed tomography. In addition, empyema was defined
as frank pus aspirated from the pleural space or positive Gram stain or cul-
ture identification of pathogens in pleural fluid1 by microbiological and
biochemical methods.Malignant pleural effusions and trauma-related effu-
sions were excluded. Two radiologists reviewed chest computed tomogra-
phy findings of all patients with suspected empyema individually until
diagnostic consensus was attained. We excluded the patients for whom
the 2 radiologists failed to reach a consensus. Empyema stage was deter-
mined using the American College of Chest Physicians (ACCP) classifica-
tion of parapneumonic effusion (Table 2).7
The surgical group was defined as patients who were treated with surgi-
cal decortication, including VATS and open thoracotomy, as the first line of
treatment for pleural empyema. The drainage group was defined as patients
who were treated with simple drainage (insertion of an 8F pigtail catheter
or a 32F large-bore chest tube).
After the intervention was completed, we evaluated the treatment
outcomes with chest computed tomography scan and judged them by com-
parison with baseline findings. Treatment success was defined as complete
evacuation of the infected pleural fluid and restoration of complete lung ex-
pansion, with follow-up radiologic examination indicating that no further
intervention was needed. Treatment failure was defined as the requirement
for additional intervention or as empyema-attributable mortality.
Statistical Analyses
Data were analyzed with the Statistical Package for the Social Sciences
version 18.0 (SPSS Inc, Chicago, Ill) and SAS version 9.2 statistical soft-
ware (SAS Institute Inc, Cary, NC). All tests were 2-sided. Categoric vari-
ables were compared by Fisher exact test and Pearson’s chi-square test, as
appropriate. Continuous variables were compared with Student t test. The
associations of clinical and laboratory parameters with treatment success
were analyzed using univariate or multivariate logistic regression model-
ing. For multivariate analysis, the variables were incorporated into theSurgery (n ¼ 27) Drainage (n ¼ 84) P value
52.0  13.2 57.4  21.7 .222
22 (81.5) 66 (78.6) .746
23.5  3.2 21.0  3.7 .002
8 (29.6) 15 (17.9) .189
0 (0-3) 1 (0-6) .014
86.9  13.7 85.6  19.5 .766
<.001
23 (85.2) 30 (35.7)
2 (7.4) 20 (23.8)
2 (7.4) 13 (15.5)
0 (0.0) 11 (13.1)
0 (0.0) 10 (11.9)
6 (0-14) 9 (0-33) .013
.087
21 (77.8) 52 (61.9)
4 (14.8) 29 (34.5)
1 (3.7) 3 (3.6)
1 (3.7) 0 (0.0)
10.3  9.0 9.3  12.8 .728
13.9  8.9 13.3  10.4 .800
ody mass index; CCI, Charlson Comorbidity Index; SD, standard deviation; ECOG,
Evaluation II; TB, tuberculosis.
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TABLE 2. Categorizing risk for poor outcome in empyema and parapneumonic effusion
Pleural space anatomy Pleural fluid bacteriology Pleural fluid chemistry Category
Risk of poor
outcome Drainage
A0 Minimal, free-flowing effusion
(<10 mm on lateral decubitus)
and Bx Culture and Gram-stain
results unknown
and Cx pH unknown 1 Very low No
A1 Small to moderate free-flowing effusion
(>10 mm and<½ hemithorax)
and B0 Negative culture and
Gram stain
and C0 pH  7.20 2 Low No
A2 Large, free-flowing effusion
(½ hemithorax), loculated effusion,
or effusion with thickened
parietal pleura
or B1 Positive culture or
Gram stain
or C1 pH<7.20 3 Moderate Yes
B2 Pus 4 High Yes
Reprinted with permission from Colice GL, Curtis A, Deslauriers J, Heffner J, Light R, Littenberg B, et al. Medical and surgical treatment of parapneumonic effusions: an
evidence-based guideline. Chest. 2000;118:1158-71.
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to adjust several baseline characteristics between the 2 treatment groups.
All tests of significance were 2 sided. Odds ratios and 95% confidence in-
tervals were also calculated.RESULTS
Demographic Characteristics
A total of 111 patients underwent surgical decortication
or simple drainage for pleural empyema between January
2008 and July 2011. Patient characteristics are shown in
Table 1. The mean patient age was 56.1  20.0 years. A to-
tal of 88 patients (79.3%) were male. The median duration
of symptoms to admission was 9.6 12.0 days, and the me-
dian duration of symptoms to treatment was 13.5  10.1
days.
Most empyemas were caused by parapneumonic effu-
sions (73 patients, 65.8%), but tuberculous empyemas
also were common (33 patients, 29.7%). Four remaining
cases (3.6%) resulted from postoperative complication,
and 1 case (0.9%) was caused by a parasite infection.
A total of 27 of 111 patients (24.3%) underwent surgical
decortication as the first line of treatment for empyema. In
the surgical group, 24 patients (88.9%) underwent open
surgery, and 3 patients (11.1%) underwent VATS. A total
of 84 of 111 patients (75.7%) were treated with simple
drainage; 56 patients (66.7%) received a large-bore chest
tube, and 28 patients (33.3%) received a small-bore pigtail
catheter.Clinical Findings and Empyema Severity in Surgical
and Simple Drainage Treatment Groups
There were no significant differences in age, gender, or
comorbidity risk factors (including diabetes mellitus) be-
tween the surgical group and the drainage group (Table
1). The mean body mass index (BMI) was higher in the sur-
gical group (23.5  3.2 kg/m2 vs 21.0  3.7 kg/m2,
P ¼ .002), and Eastern Cooperative Oncology Group
(ECOG) performance status scores tended to be lower in
the surgical group (P<.001). The median Charlson Comor-
bidity Index (CCI) was higher in the drainage groupThe Journal of Thoracic and Ca(0 [range, 0-3] vs 1 [range, 0-6] in the surgical and drainage
groups, respectively; P¼ .014). The median Acute Physiol-
ogy and Chronic Health Evaluation II (APACHE II) score at
diagnosis also was higher in the drainage group (6 [range,
0-14] vs 9 [range, 0-33] in the surgical and drainage groups,
respectively; P ¼ .013).
There were no significant differences in serum white
blood cell counts and serum albumin levels between the 2
treatment groups. The mean erythrocyte sedimentation
rate was significantly higher in the surgical group (83.73
 33.34 mm/h vs 67.17  33.39 mm/h in the drainage
group; P ¼ .047), as was serum C-reactive protein
(213.32  140.28 mg/L vs 155.18  113.30 mg/L in the
drainage group; P ¼ .035) (Table 3). The surgical group
showed a significantly higher rate of gross pus observed
in the pleural fluid (11/14 cases; 78.6%) than the drainage
group (35/73 cases, 47.9%; P ¼ .035).
Most patients had clinically advanced empyema. Of 111
enrolled patients, 61 (55.0%) were staged as category 3 and
46 (41.4%) were staged as category 4. There was no signif-
icant difference in initial disease severity between the 2
treatment groups (P ¼ .703, Table 3).
Subanalysis With Propensity-Scored Matching
Because several baseline characteristics, including BMI,
CCI, ECOG, and APACHE II scores, were significantly dif-
ferent between the surgical and drainage groups, we used
propensity-scored matching analysis to investigate whether
these factors affected treatment success rate after surgical
decortication. After propensity-scored matching, 61 pa-
tients were excluded from the analysis and 50 patients (20
from the surgical group and 30 from the drainage group)
were further analyzed. After matching, the baseline BMI,
ECOG, CCI, and APACHE II scores showed no difference
between the 2 groups (Table 4).
Treatment Outcomes Relative to TreatmentModality
Of 111 patients, 75 (67.6%) showed treatment success
after the first intervention. The surgical group showed
a 96.3% success rate (26/27 patients), whereas the drainagerdiovascular Surgery c Volume 145, Number 4 935
TABLE 3. Radiologic and laboratory findings and severity of pleural empyema
Variable Total (N ¼ 111) Surgery (n ¼ 27) Drainage (n ¼ 84) P value
Laboratory findings
WBC/mm2 12,799.5  7861.13 13,776.7  5344.25 12,485.4  8517.21 .460
ESR, mm/h* 71.3  33.96 83.7  33.34 67.2  33.39 .047
CRP, mg/Ly 169.7  122.52 213.3  140.28 155.2  113.30 .035
Albumin, g/dL 3.33  0.60 3.48  0.52 3.28  0.62 .143
Pleural fluid
pHz 7.03  0.746 7.04  0.116 7.02  0.814 .934
WBCs/mm2z 13,247.9  36,202.03 9801.4  12,393.83 13,908.9  39,178.26 .700
Glucose, mg/dLx 89.5  63.76 103.0  51.16 86.9  66.10 .492
Gross pus, n (%)z 46 (52.9%) 11 (78.6%) 35 (47.9%) .035
Category, n (%)k .703
1 1 (0.9%) 0 (0.0%) 1 (1.2%)
2 3 (2.7%) 0 (0.0%) 3 (3.6%)
3 61 (55.0%) 16 (59.3%) 45 (53.6%)
4 46 (41.4%) 11 (40.7%) 35 (41.7%)
WBC, ESR, CRP, albumin, pH, and glucose values are all presented as mean units  standard deviation. WBC, White blood cell; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein. *A total of 88 of 111 cases were examined in this test. yA total of 104 of 111 cases were examined in this test. zA total of 87 of 111 cases were examined
in this test. xA total of 55 of 111 cases were examined in this test. kCategories for poor outcome in patients with parapneumonic effusion.7
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(P<.001, Table 5). In 35 drainage group cases with treat-
ment failure, 24 patients were treated with surgical treat-
ment as a next intervention; 2 patients who initially
received pigtail catheter drainage were treated with
a large-bore chest tube insertion as a follow-up therapy
(Table E1). Eleven patients in the drainage group and 1 pa-
tient in surgical group who experienced treatment failure
died of empyema-attributable causes (10.8% of enrolled
population; Table 5). The overall survival was 89.2% (99/
111 enrolled patients), and survivals were not significantly
different between the 2 treatment groups (96.3% vs 86.9%
in the surgical and drainage groups, respectively; P ¼ .172;
Table 5). There was no significant difference of treatment
outcome between organisms. But survival of Gram-
negative organisms was lower than of others (Table E2).TABLE 4. Clinical and laboratory characteristics after propensity-scored
Variables Total (N ¼ 50)
Age, y 49.8  17.5
Gender, male, n (%) 40 (80.0%)
BMI, kg/m2 23.2  3.0
Diabetes, n (%) 11 (22.0%)
CCI, median (range) 0 (0-6)
Mean arterial pressure, mm Hg 86.6  17.2
ECOG, n (%)
0 40 (80.0%)
1 5 (10.0%)
2 4 (8.0%)
3 1 (2.0%)
APACHE II score at diagnosis, median (range) 5 (0-33)
Duration of symptoms to admission, d 9.9  8.7
Duration of symptoms to treatments, d 12.4  8.5
Years, kilograms/meters squared, millimeters of mercury, and days are all presented as me
Index; ECOG, Eastern Cooperative Oncology Group; APACHE II, Acute Physiology and
936 The Journal of Thoracic and Cardiovascular SurgTreatment to discharge duration (10.0  5.5 days vs 14.5
 16.0 days in the surgical and drainage groups, respec-
tively, P ¼ .157) and hospitalization duration (13.6  7.4
days vs 18.5  19.2 days in the surgical and drainage
groups, respectively; P ¼ .198) tended to be shorter in the
surgical group, although this did not attain statistical signif-
icance (Table 5).
After propensity-scored matching analysis, the surgical
group showed a significantly greater treatment success
rate of 95.0% (19/20 patients) versus a success rate of
56.7% (17/30 patients) in the drainage group (P ¼ .003;
Table 5). The surgical group also showed a trend of short-
ened treatment to discharge duration (9.8  6.2 days vs
12.2 8.5 days in the drainage group), although this differ-
ence was not statistically significant (P ¼ .272). The pa-
tients who underwent surgery as a second interventionmatching
Surgery (n ¼ 20) Drainage (n ¼ 30) P value
53.0  13.7 47.7  19.5 .300
15 (75.0%) 25 (83.3%) .470
23.7  3.5 22.9  2.7 .362
6 (30.0%) 5 (16.7%) .265
0 (0-3) 0 (0-6) .611
87.1  14.7 86.2  18.9 .864
.841
16 (80.0%) 24 (80.0%)
2 (10.0%) 3 (10.0%)
2 (10.0%) 2 (6.7%)
0 (0.0%) 1 (3.3%)
6 (0-11) 5 (0-33) .554
9.6  9.1 10.1  8.5 .839
13.5  8.9 11.8  8.3 .500
an values  standard deviation. BMI, Body mass index; CCI, Charlson Comorbidity
Chronic Health Evaluation II.
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TABLE 5. Treatment outcomes according to the treatment modality
Variables
All study subjects (N ¼ 111) After propensity-scored matching (N ¼ 50)
Total
(N ¼ 111)
Surgery
(n ¼ 27)
Drainage
(n ¼ 84) P value
Total
(N ¼ 50)
Surgery
(n ¼ 20)
Drainage
(n ¼ 30) P value
Treatment success, n (%) 75 (67.6%) 26 (96.3%) 49 (58.3%) <.001 36 (72.0%) 19 (95.0%) 17 (56.7%) .003
Survival, n (%) 99 (89.2%) 26 (96.3%) 73 (86.9%) .172 48 (96.0%) 19 (95.0%) 29 (96.7%) .768
Duration of treatment to discharge, d 13.4  14.3 10.0  5.5 14.5  16.0 .157 11.2  7.7 9.8  6.2 12.2  8.5 .272
Duration of hospitalization, d 17.3  17.2 13.6  7.4 18.5  19.2 .198 13.8  8.2 13.6  8.4 13.9  8.2 .884
Days are presented as mean  standard deviation.
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nificantly prolonged hospital stay compared with the pa-
tients who underwent surgical decortication as a first
intervention (Table E3).
Univariate data analyses are summarized in Table 6.
Significant predictors of overall treatment success included
an APACHE II score less than 20 (P ¼ .008), mean arterial
pressure 60mmHg ormore (P¼ .008), serum albumin level
3 g/dL or more (P¼ .021), and surgical decortications as the
choice of first intervention (P<.001). Pleural fluid bacterial
culture positivity was significantly associated with a poor
treatment outcome (P < .001). After propensity-scored
matching analysis, only surgical decortications as a choice
of the first intervention remained as a significant predictor
of treatment success (P ¼ .003), whereas pleural fluid bac-
terial culture positivity remained a predictor of treatment
failure (P<.001).
In a multivariate logistic regression after matching anal-
ysis, the strongest predictor of treatment success was surgi-
cal decortication as the choice of first intervention (odds
ratios of treatment success, 14.53; 95% confidence inter-
val, 1.715-123.074; P ¼ .014) (Figure 1). Comprehen-
sively, the best predictor of empyema treatment success
was the selection of surgical decortication as the first line
of treatment.TABLE 6. Univariate analysis of overall treatment success
Variables
All study subjects (
Success (n ¼ 75) Failure (
Age, y 56.1  19.8 56.1  2
BMI 17 kg/m2, n (%) 69 (92.0%) 29 (80
ECOG, median (range) 0 (0-4) 1 (0-
APACHE II<20, n (%) 72 (96.0%) 29 (80
CCI, median (range) 0 (0-6) 1 (0-
Mean blood pressure  60, n (%) 73 (97.3%) 30 (83
Serum albumin  3.0, n (%) 56 (74.7%) 19 (52
Loculation on CT, n (%) 56 (74.7%) 30 (83
Pleural fluid pH  7.2, n (%) 10 (18.2%) 7 (21
Pleural fluid glucose, mg/dL 93.7  62.2 80.9  6
Pleural fluid bacterial smear positivity, n (%) 0 (0.0%) 2 (6.
Pleural fluid bacterial culture positivity, n (%) 0 (0.0%) 7 (21
Decortication as a first treatment, n (%) 26 (34.7%) 1 (2.
Years and milligrams/deciliter are presented as mean values  standard deviation. BMI, B
Physiology and Chronic Health Evaluation; CCI, Charlson Comorbidity Index; CT, comp
The Journal of Thoracic and CaDISCUSSION
We showed that selecting surgical decortication as first-
line therapy for advanced pleural empyema is an indepen-
dent and important positive prognostic factor for treatment
success. Light8 showed that gross pus in pleural fluid, bac-
terial smear and culture positivity, blood glucose less than
40 mg/dL, pleural effusion pH less than 7.2, and loculation
are the poor prognostic factors in parapneumonic effusion
and empyema treatment outcomes. We confirmed that pleu-
ral fluid bacterial culture positivity had a significant nega-
tive predictive effect on empyema treatment outcome but
were unable to verify the importance of the other factors.
The disparity between our findings and those of Light8
are possibly because most patients in our study had
advanced-stage empyema and already showed gross pleural
pus, low pleural fluid pH, and loculation. We categorized
patients with parapneumonic effusion by risk for poor out-
come, according to evidence-based guidelines established
by an expert panel of the ACCP (Table 2).7 In our study,
96.7% of patients were categorized as moderate (category
3) or high (category 4) risk for a poor outcome (Table 3).
Surgical decortication was highly successful in treating
advanced empyema. In addition, decortication showed
a tendency to reduce the treatment to discharge time com-
pared with tube drainage. Wong and colleagues9 reportedN ¼ 111) After propensity-scored matching (N ¼ 50)
n ¼ 36) P value Success (n ¼ 36) Failure (n ¼ 14) P value
0.6 .985 51.6  17.9 45.2  16.1 .254
.6%) .079 36 (100.0%) 14 (100.0%)
4) .061 0 (0-3) 0 (0-2) .821
.6%) .008 34 (94.4%) 13 (92.9%) .832
5) .279 0 (0-6) 0 (0-5) .190
.3%) .008 34 (94.4%) 13 (92.9%) .832
.8%) .021 32 (88.9%) 12 (85.7%) .756
.3%) .306 25 (69.4%) 12 (85.7%) .303
.9%) .675 3 (11.1%) 3 (21.4%) .375
7.8 .490 94.3  65.3 98.0  83.7 .900
3%) .061 0 (0.0%) 0 (0.0%) NS
.9%) <.001 0 (0.0%) 2 (14.3%) .044
8%) <.001 19 (52.8%) 1 (7.1%) .003
ody mass index; ECOG, Eastern Cooperative Oncology Group; APACHE II, Acute
uted tomography; NS, not significant.
rdiovascular Surgery c Volume 145, Number 4 937
FIGURE 1. Multivariate analysis of overall treatment success. Odds ratios (95% confidence intervals) of overall treatment success with BMI of 17 kg/m2
or greater, ECOG score, APACHE II score less than 20, mean arterial pressure 60mmHg or greater, serum albumin 3.0 g/dL or greater, and decortications as
a first treatment were analyzed using logistic regression in stepwise manner. After propensity-scored matching adjustment, decortication as a first interven-
tion remained themost important predictive factor of a successful treatment outcome.APACHE II,Acute Physiology and Chronic Health Evaluation II; BMI,
body mass index; BP, blood pressure; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; OR, odds ratio.
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hospitalization duration compared with tube drainage treat-
ment in pediatric patients. Thourani and colleagues10
reported that surgical decortications reduced the hospital
stay compared with simple drainage through a catheter or
chest tube. In the last study, surgical decortications also
reduced the duration of intensive care unit stay compared
with patients treated with simple drainage.
We evaluated a potential role for nutritional status, perfor-
mance status, and comorbidities assessed with BMI, ECOG,
and CCI in affecting empyema treatment outcome.Wozniak
and colleagues11 reported that using simple drainage as
a first treatment compared with surgical intervention was
the most powerful prognostic factor for first treatment fail-
ure, and that first treatment failure is an important predictive
factor of mortality in adult patients with empyema. Accord-
ing to the meta-analysis that followed ACCP guidelines,7
surgical treatment for empyema, regardless of whether it
was via VATS access or open access, showed a superior
success rate when compared with therapeutic thoracocente-
sis, tube thoracotomy, and fibrinolysis. Also, surgical treat-
ment was superior to simple drainage modalities in reducing
total mortality. LeMense and colleagues12 suggested using
a short trial of closed-chest drainage for 24 to 48 hours after
radiologic imaging in patients with empyema, with early
aggressive surgical intervention performed in patients who
showed no rapid resolution, and reportedminimalmorbidity
and mortality. Likewise, other investigators10,13-15 reported
that early surgical decortication as a first intervention or
after a short trial of simple drainage showed an excellent
success rate and minimal mortality in patients with
multiloculated effusions and advanced empyema.
In our study, the surgical treatment group showed a more
favorable BMI, a better performance status, less comorbid-
ity, and a lower initial APACHE II score compared with the938 The Journal of Thoracic and Cardiovascular Surgsimple drainage treatment group. This suggests that
surgeons tend to choose surgical treatment as a first inter-
vention in relatively healthy patients. However, after
adjusting the differences of baseline characteristics with
propensity-scored matching analysis, multivariate analysis
showed that surgical decortication remains favorable for
empyema treatment success and patient survival. In our
clinical experience, highly debilitated patients are less com-
monly referred for surgical decortication as a first interven-
tional strategy.
Surgical decortication involves the removal of all fibrous
tissue from the pleura and the evacuation of all pus and
debris from the pleural space.16 Decortication is a major
thoracic surgery requiring a large incision and is often dif-
ficult to perform in debilitated patients.8 However, previous
studies showed that decortications did not require long
hospitalization stays. According to a study on surgical man-
agement of empyema,13 the median postoperative stay was
reported as only 7 days. In several studies, VATS decortica-
tions showed equal or lesser morbidity and mortality com-
pared with open surgery, and the VATS approach also
reduced the hospitalization duration.17-19
The greater cost of surgical treatment versus simple
drainage treatment is often considered to be a disadvantage
of this approach, despite its superior success rate in patients
with empyema. St Peter and colleagues20 reported that
VATS decortication did not result in increased treatment
success and had a higher cost compared with fibrinolysis
in pediatric patients with empyema. However, that study
simply compared procedure charge. When considering total
treatment costs, it is essential to appreciate that surgical
decortication reduces hospitalization duration and rarely re-
quires initiation of additional treatment modalities because
of treatment failure. Surgical decortication is not necessar-
ily more expensive than simple drainage intervention. Inery c April 2013
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tal hospital charge for surgical decortication was not signif-
icantly different compared with the costs for catheter
drainage and tube thoracotomy. In fact, surgical decortica-
tion resulted in a lower cost compared with the treatment
failure group that had undergone catheter drainage or tube
thoracotomy.
Study Limitations
There are several limitations in this study. First, it was
a retrospective study, and the study population and clinical
setting were selective and limited; thus, selection bias may
have occurred. We attempted to adjust for this through the
use of propensity score matching, but that did not com-
pletely overcome selection bias. Second, tuberculous empy-
emas were analyzed with nontuberculous empyemas. In our
study, 33 patients (29.7%) had tuberculous empyema. Tu-
berculous empyema is a common cause of empyema in in-
termediate (eg, South Korea) and countries with a high TB
burden. Early thoracoscopic intervention showed good out-
comes in previous studies.3,21 In our study, the outcomes of
surgical treatment for tuberculous and nontuberculous
empyema were not different.
CONCLUSIONS
The choice of the first interventional strategy for empy-
ema is critical for treatment success. Even after adjusting
for confounding variables, surgical decortication with
VATS or thoracotomy is the optimal first line of treatment
in patients with advanced empyema.
The authors thank the Medical Research Supporting Section of
Yonsei University College of Medicine for statistical support.
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TABLE E1. Choice of next treatment modalities and death in patients
with treatment failure
Variable
Treatment failure
Total
(N ¼ 36)
Surgery
(n ¼ 1)
Drainage
(n ¼ 35)
Next treatment modality
Surgical decortications 24 (66.7%) 0 (0.0%) 24 (68.6%)
Chest tube drainage 2 (5.6%) 0 (0.0%) 2 (5.7%)
No treatment 10 (27.8%) 1 (100.0%) 9 (25.7%)
Death 12 (33.3%) 1 (100.0%) 11 (31.4%)
All variables are presented as N (%).
TABLE E2. Treatment outcomes according to pathogens
Total
(N ¼ 57)
Treatment
success
(n ¼ 28)
Survival
(n ¼ 41)
Mycobacterium tuberculosis 32 (56.1%) 23 (82.1%) 32 (78.0%)
Gram (þ) 4 (7.0%) 1 (3.6%) 3 (7.3%)
Gram () 8 (14.0%) 2 (7.1%) 3 (7.3%)
Anaerobes 1 (1.8%) 1 (3.6%) 1 (2.4%)
Fungus 12 (21.1%) 1 (3.6%) 2 (4.9%)
P value .068 .001
Pathogens were isolated in only 57 of 111 patients.
TABLE E3. Outcome of surgical treatment as a first intervention
compared with surgical treatment as a second intervention
Surgery
as a first
intervention
(n ¼ 27)
Surgery
as a second
intervention
(n ¼ 24) P value
Survival, n (%) 26 (96.3%) 23 (95.8%) .932
Total length of
hospital stay, d
13.56  7.42 26.83  23.25 .007
The duration of
treatment to
discharge, d
10.00  5.54 23.92  22.13 .003
Days are presented as mean  standard deviation.
General Thoracic Surgery Shin et al
939.e1 The Journal of Thoracic and Cardiovascular Surgery c April 2013
G
T
S
